Emergent Biosolutions (NYSE:EBS) Issues Quarterly Earnings Results

Emergent Biosolutions (NYSE:EBS) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.54), FiscalAI reports. Emergent Biosolutions had a return on equity of 20.85% and a net margin of 9.62%.The company had revenue of $148.70 million for the quarter, compared to analyst estimates of $217.50 million.

Emergent Biosolutions Price Performance

EBS traded up $0.11 on Thursday, reaching $11.12. The stock had a trading volume of 1,398,387 shares, compared to its average volume of 827,449. The company has a current ratio of 5.76, a quick ratio of 3.15 and a debt-to-equity ratio of 1.14. The company has a market capitalization of $584.02 million, a price-to-earnings ratio of 8.55 and a beta of 2.35. Emergent Biosolutions has a fifty-two week low of $4.02 and a fifty-two week high of $14.06. The firm has a 50-day moving average of $11.79 and a 200-day moving average of $10.39.

Insider Activity

In related news, Director Ronald Richard sold 21,984 shares of the firm’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $11.97, for a total value of $263,148.48. Following the completion of the transaction, the director owned 98,417 shares in the company, valued at $1,178,051.49. This trade represents a 18.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co acquired a new stake in shares of Emergent Biosolutions during the fourth quarter worth $45,000. Legal & General Group Plc acquired a new stake in Emergent Biosolutions during the 2nd quarter worth about $31,000. Raymond James Financial Inc. acquired a new stake in Emergent Biosolutions during the 2nd quarter worth about $53,000. Kemnay Advisory Services Inc. bought a new position in shares of Emergent Biosolutions in the 4th quarter worth about $107,000. Finally, Abel Hall LLC bought a new stake in shares of Emergent Biosolutions during the 4th quarter valued at about $129,000. Institutional investors own 78.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on EBS shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Emergent Biosolutions in a research note on Tuesday, December 16th. Wall Street Zen raised shares of Emergent Biosolutions from a “buy” rating to a “strong-buy” rating in a report on Sunday, November 30th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Emergent Biosolutions in a research note on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $15.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.